CMS
Senators Reintroduce Bill to Establish Medicare Coverage Pathway for MCED Tests
The bill would allow Medicare to cover MCED tests following approval by FDA and ensure their use would not impact coverage of traditional screenings.
CMS Contractor Novitas Rescinds Coverage for Multiple Cancer Genetic Tests
Novitas reviewed, analyzed, and published literature for a variety of genetic oncology tests and highlighted several that it claims are not medically reasonable or necessary.
Interpace Biosciences to Stop Offering Pancreatic Cancer Test After Losing CMS Reimbursement
Novitas said in its coverage determination that the test has not demonstrated incremental clinical value in the prognosis of pancreatic cysts and associated cancer.
CMS Contractor Proposes Noncoverage of Castle Biosciences Skin Cancer Test
The contractor said that the test has not yet demonstrated definitive value above the combination of available clinical, pathological, and staging criteria in accurate risk stratification.
Devyser Gets CLIA Certification for Atlanta Lab
The Sweden-based firm said it will use the laboratory to perform testing for hereditary diseases, oncology, post-transplant monitoring, and other patient management.